YOLFTbeta
Sunshine Guojian Pharmaceutical Shanghai Co Ltd

Sunshine Guojian Pharmaceutical Shanghai Co Ltd

688336 · SHG · Healthcare / Biotechnology

32.08CNY-1.93 (-5.67%)

Price History

Full chart

Market Stats

Previous Close34.01
Open33.60
Day Range31.93 – 33.97
52-Week Range33.93 – 65.85
Volume6.04M
Market Cap37.13B
P/E (TTM)12.08
Forward P/E0.00
EPS3.43
Dividend Yield1.14%
Beta0.34
50-Day Avg42.91
200-Day Avg45.14

About

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include Enbrel, a recombinant human type II tumor necrosis factor receptor-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation; and Enbrel, an anti-IL-17A humanized monoclonal antibody ambroxol injection for the treatment of moderate to severe plaque psoriasis. The company was founded in 2002 and is based in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Yanli Liu
  • Employees1.02K
  • HeadquartersNo. 399, Libing Road, Shanghai, China, 201203, China
  • Websitehttps://3s-guojian.com

Leadership

  • Ms. Yanli LiuGM & Director · b. 1981
  • Ms. Hongmei NiuChief Financial Officer · b. 1990
  • Mr. Qi ZhangSecretary of Board of Directors · b. 1984
  • Lirong ZhengAccounting Supervisor

Financials

Income Statement

Currency: CNY2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue34.56M92.49M159.38M245.26M342.94M475.21M595.51M727.84M775.85M877.35M961.37M1.10B1.14B1.18B655.01M928.81M825.49M1.01B1.19B4.20B
Growth (%)-+167.66%+72.32%+53.88%+39.83%+38.57%+25.32%+22.22%+6.60%+13.08%+9.58%+14.78%+3.52%+3.08%-44.37%+41.80%-11.12%+22.84%+17.70%+251.81%
Cost of Revenue10.83M17.45M15.33M23.15M28.64M38.40M39.37M40.17M54.38M56.15M68.02M104.72M118.28M145.97M102.29M210.02M204.81M223.04M304.70M332.95M
Gross Profit23.72M75.05M144.05M222.11M314.30M436.81M556.14M687.67M721.47M821.20M893.36M998.70M1.02B1.03B552.72M718.79M620.68M790.99M888.86M4.20B
Gross Margin68.65%81.14%90.38%90.56%91.65%91.92%93.39%94.48%92.99%93.60%92.93%90.51%89.64%87.60%84.38%77.39%75.19%78.00%74.47%100.00%
Operating Expense60.84M73.06M98.94M134.64M170.20M253.65M328.19M417.07M579.54M634.24M629.97M557.83M602.51M771.59M755.79M762.42M583.74M472.78M162.34M905.80M
Operating Income-37.12M1.99M45.11M87.47M144.10M183.15M227.95M270.60M141.93M186.96M263.38M440.86M421.45M259.83M-203.07M-43.63M36.94M318.21M726.52M3.29B
Operating Margin-107.42%2.15%28.30%35.67%42.02%38.54%38.28%37.18%18.29%21.31%27.40%39.95%36.90%22.07%-31.00%-4.70%4.48%31.38%60.87%78.43%
EBITDA7.82M29.97M73.44M120.26M166.59M218.00M261.91M399.27M302.62M303.86M384.80M515.77M531.53M361.49M-146.26M82.24M152.68M408.31M836.34M3.41B
EBITDA Margin22.63%32.40%46.08%49.03%48.58%45.88%43.98%54.86%39.00%34.63%40.03%46.74%46.53%30.70%-22.33%8.85%18.50%40.27%70.07%81.27%
Net Income-31.51M17.34M62.44M110.31M156.51M196.30M256.84M295.26M212.41M210.70M268.10M388.72M369.66M229.30M-217.46M18.06M49.30M294.61M704.58M2.94B
Net Income Margin-91.17%18.74%39.17%44.98%45.64%41.31%43.13%40.57%27.38%24.02%27.89%35.23%32.36%19.47%-33.20%1.94%5.97%29.05%59.03%69.98%
R&D-------74.84M124.44M177.77M175.61M122.26M198.71M278.89M340.25M455.09M313.28M282.30M356.49M434.95M
R&D as % of Total Revenue-------10.28%16.04%20.26%18.27%11.08%17.40%23.69%51.95%49.00%37.95%27.84%29.87%10.36%
Interest Expense285.93K1.13M2.09M4.57M------152.71K-1.60M95.78K122.17K171.96K1.32M1.59M1.18M569.40K
Interest Expense % of Total Revenue0.83%1.22%1.31%1.86%------0.02%-0.14%0.01%0.02%0.02%0.16%0.16%0.10%0.01%

Balance Sheet

Currency: CNY2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets516.86M537.74M618.78M742.18M1.13B1.59B1.95B2.28B2.29B2.57B2.89B3.34B3.70B3.32B4.95B4.89B5.10B5.31B5.97B8.96B
Total Liabilities72.09M74.10M94.79M76.38M74.71M305.07M415.74M289.98M85.56M98.42M340.22M426.86M426.97M416.34M433.44M349.73M498.88M426.47M428.15M-5.86B
Total Equity444.77M463.64M523.99M665.80M984.36M1.18B1.44B1.73B1.95B2.20B2.46B2.85B3.22B2.87B4.50B4.54B4.61B4.90B5.57B5.86B
Cash40.75M62.91M80.35M203.42M447.99M766.39M939.24M877.04M526.53M575.58M142.67M317.58M202.05M890.85M1.78B1.61B1.09B933.26M459.49M193.27M
Total Debt27.00M57.00M57.00M20.00M-190.77M191.35M194.41M--------150.10M50.03M50.02M-
Net Debt-13.75M-5.91M-23.35M-183.42M-447.99M-575.62M-747.89M-682.64M-526.53M-575.58M-142.67M-317.58M-202.05M-890.85M-1.78B-1.61B-940.63M-883.24M-409.47M-

Cash Flow

Currency: CNY2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-26.06M29.34M98.35M166.48M181.81M239.71M349.54M276.41M264.01M335.69M354.35M235.11M361.28M587.64M-40.08M-243.79M233.49M416.35M281.14M3.04B
Investing Cash Flow-39.52M-14.17M-76.98M-32.43M-79.28M-139.96M-161.94M-323.48M-407.75M-287.47M-407.70M-270.10M-266.73M369.25M-529.60M-18.50M-916.69M-479.42M-750.14M-
Financing Cash Flow29.91M7.32M-3.92M-10.98M139.83M118.17M87.55M-14.61M-206.68M--152.71K3.00M-3.00M-672.13M1.86B151.08M151.08M-101.47M-52.37M-
Capital Expenditure19.52M35.03M77.13M32.80M56.17M140.02M162.08M282.08M334.05M201.13M104.71M69.12M90.06M130.24M226.98M263.82M221.26M235.75M280.78M252.95M
Free Cash Flow-45.58M-5.69M21.22M133.69M125.64M99.69M187.46M-5.67M-70.05M134.56M249.64M165.99M271.23M457.39M-267.06M-507.61M12.23M180.61M354.31K2.79B
Dividends Paid1.59M1.68M3.92M5.48M2.22M-11.68M---152.71K--716.50M1.22M1.22M1.22M1.47M51.19M76.46M
FCF to OCF174.91%-19.40%21.58%80.30%69.11%41.59%53.63%-2.05%-26.53%40.08%70.45%70.60%75.07%77.84%666.34%208.22%5.24%43.38%0.13%91.69%
Dividend Paid to FCF-3.49%-29.53%18.47%4.10%1.77%-6.23%---0.06%--156.65%-0.46%-0.24%9.98%0.81%14448.78%2.74%

Earnings

Report DateSep 30, 2020Dec 31, 2020Apr 26, 2021Aug 19, 2021Oct 21, 2021Mar 31, 2022Apr 28, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate-----------
EPS Actual0.00-0.26-0.050.09-0.030.020.00-0.010.010.080.05
Surprise-----------
Timing-----Pre-marketPre-market----

Key Statistics & Ratios

Market Cap37.13B
Enterprise Value35.75B
Trailing P/E12.08
Forward P/E0.00
Price / Sales8.40
Price / Book4.36
EPS3.43
Book Value9.49
Revenue (TTM)4.42B
Gross Profit (TTM)4.11B
EBITDA3.43B
Profit Margin69.65%
Operating Margin29.47%
Return on Equity43.53%
Return on Assets27.84%
Shares Outstanding896.23M
Shares Float138.48M
Beta0.34
Dividend Yield1.14%
Dividend Rate0.47
Payout Ratio13.79%

Dividends

20262×
0.04Nov 6, 20260.45Jun 18, 2026
20252×
0.02Nov 7, 20250.06Jun 13, 2025
20242×
0.02Sep 27, 20240.03Jun 26, 2024

Stock Splits

  • Jun 18, 20261.45:1